1. Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
- Author
-
Thomas, Sarah E., Seyger, Marieke M. B., Mangnus, Josje E., Otero, Marisol E., Gostynski, Antoni H., Njoo, Marcellus D., Ossenkoppele, Paul M., Haeck, Inge M., Hendricksen-Roelofzen, Judith H. J., Körver, John E. M., Dodemont, Sharon R. P., Tupker, Ron A., Berends, Maartje A. M., Weppner-Parren, Lizelotte M. J. T., Keijsers, Romy R. M. C., Oostveen, Annet M., Peters, Bas, Mommers, Roland, van Doorn, Martijn B. A., and Tjioe, Milan
- Subjects
THERAPEUTIC use of monoclonal antibodies ,PSORIASIS ,TERMINATION of treatment ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,ODDS ratio ,RESEARCH ,CONFIDENCE intervals ,INTERLEUKINS ,EVALUATION ,CHEMICAL inhibitors - Abstract
The article focuses on evaluating real-world outcomes in psoriasis treatment when switching to interleukin-23 inhibitors (IL-23i) after ineffectiveness of ustekinumab. It explores drug survival (DS) and effectiveness of IL-23i in patients who previously discontinued ustekinumab due to ineffectiveness compared to those who had not used ustekinumab before. It uses data from the BioCAPTURE registry to analyze outcomes such as Psoriasis Area and Severity Index (PASI) scores and DS rates.
- Published
- 2024
- Full Text
- View/download PDF